Clinical Evaluation of Therapeutic Meibomian Gland Expression

Visual Acuity Clinical Trial

Official title:

Clinical Evaluation of Therapeutic Meibomian Gland Expression

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04997135
• Other study ID #: CR-6455
• Status: Completed
• Start date: August 15, 2021
• Est. completion date: November 11, 2021

Study information

• Verified date: November 2021
• Source: Johnson & Johnson Vision Care, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This will be a single centre pilot study to evaluate appearance of the Meibomian glands.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 16
• Est. completion date: November 11, 2021
• Est. primary completion date: November 11, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• Potential subjects who meet any of the following criteria will be excluded from

participating in the study:

1. Read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form.

2. Appear able and willing to adhere to the instructions set forth in this clinical protocol.

3. Be between 18 and 60 (inclusive) years of age at the time of screening. Inclusion Criteria at Baseline Evaluation.

4. The subject must have visual acuity of 0.2 high contrast logMAR or better in their current correction or unaided in each eye.

5. The subject must have at least 10 Meibomian glands yielding liquid secretion (MGYLS) in central lower eyelid region in each eye.

6. The subject eyelids must be easy to evert, at the Investigator's discretion.

Exclusion Criteria:

• Potential subjects who meet any of the following criteria will be excluded from

participating in the study:

1. Be currently pregnant or breastfeeding.

2. By self-report, have any ocular or systemic disease, allergies, infection, or use of medication that might contraindicate or interfere with contact lens wear, or otherwise compromise study endpoints, including infectious disease (e.g., hepatitis, tuberculosis), contagious immunosuppressive disease (e.g., Human Immunodeficiency Virus [HIV]), autoimmune disease (e.g., rheumatoid arthritis, Sjögren's syndrome), or history of serious mental illness or seizures. See Section 9.1 for additional details regarding excluded systemic medications.

3. Have any known hypersensitivity or allergic reaction to any of the known ingredients in the anesthetic (proxymetacaine hydrochloride) or sodium fluorescein.

4. Have a history of cardiac disease or hyperthyroidism.

5. Have had any previous ocular or intraocular surgery (e.g., radial keratotomy, PRK, LASIK, cataract etc.)

6. Have participated in any ophthalmic clinical trial within 14 days prior to study enrolment.

7. Be an employee or immediate family member of an employee of clinical site (e.g., Investigator, Coordinator, Technician).

8. Have a history of amblyopia or strabismus.

9. Have a history of contact lens wear. A trial period (up to one week) in the past is allowed.

10. Wear eye makeup on the days of the study visits.

11. Have clinically significant (grade 3 or higher on the Efron grading scale) slit lamp findings (e.g., corneal edema or neovascularization, conjunctival or limbal redness) or any other abnormality which would normally contraindicate participation in the study.

12. Have any ocular infection.

13. Have central lower eyelid Meibomian gland atrophy that exceeds 25%.

Related Conditions & MeSH terms

• Visual Acuity

Locations

Country	Name	City	State
United Kingdom	The University of Manchester	Manchester

Sponsors (1)

Lead Sponsor	Collaborator
Johnson & Johnson Vision Care, Inc.

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Meibomian Gland Appearance	Meibomian gland appearance will be evaluated on both eyes using a custom image analysis algorithm, which calculates length ratio, width, area, intensity, tortuosity, and contrast	up to 2-week follow-up